| MERCK KGAA O.N. | 104.00 / +0.63% |
| Date/Time | 12/05 / 17:35 |
| Chg. / Chg.(%) | 0.65 / +0.63% |
| Bid | - |
| Ask | - |
| Open | 103.80 |
| Previous Close | 103.35 |
| High | 104.70 |
| Low | 103.35 |
| Volume [EUR] | 63,446,092.05 |
| Volume [Units] | 609,950 |
| Price fixings | 2066 |
| ISIN | DE0006599905 |
| Security | MRK |
| Exchange | Xetra |
| Type | Stock |
| Exchange | Last | Volume | |
|---|---|---|---|
| Xetra | 104.00 |  |
609,950 |
| Cboe Europe .. | 104.20 | |
112,852 |
| Turquoise | 104.20 | |
82,549 |
| Cboe Europe .. | 104.20 | |
64,778 |
| London Inter.. | 104.00 | |
22,735 |
| TradeGate | 104.700 |  |
5,203 |
| Stuttgart | 104.350 | |
2,240 |
| München | 104.05 | |
166 |
| Frankfurt | 104.2000 | |
160 |
| Borsa Italia.. | 103.95 |  |
140 |
| Vienna Globa.. | 104.20 | |
0 |
| Hamburg | 103.35 | |
0 |
| Düsseldorf | 104.20 | |
0 |
| Hannover | 103.35 | |
0 |
| Berlin | 104.00 | |
0 |
| Lang & Schwa.. | 104.200 | |
|
| gettex | 104.050 | |
|
| Nasdaq Other.. | 113.6500 | 500 | |
| SIX Swiss Ex.. | 102.20 | ||
| SIX Swiss Ex.. | 97.00 | ||
| EUREX | Options | ||
News
- RenovaCare Stockholder Update and 2020 Outlook from the CEO
14:30 - GlobeNewswire - Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update
11/12/2019 / 14:00 - GlobeNewswire - Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
11/09/2019 / 14:02 - GlobeNewswire - Merck says Q3 sales jump 12% YoY to $12.4B
10/29/2019 / 11:49 - TeleTrader - Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, France
09/27/2019 / 12:05 - GlobeNewswire
Real-time